Loading patent…
AssigneeSanofi
InventorsZhi-Yong YANG, Gary J. Nabel, Ling Xu, Jochen Beninga, Jochen Kruip, Ercole Rao, Wulf Dirk Leuschner, Christian Beil, Christian Lange
Estimating the term…
Provided herein are compositions comprising trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/AIDS.
1-139. (canceled)
140:
141:
142:
143:
144:
145:
An expression vector comprising the nucleic acid molecule of claim 143.
An expression vector comprising the nucleic acid molecule of claim 144.
An expression vector comprising the nucleic acid molecule of claim 145.
An isolated host cell comprising the nucleic acid molecule of claim 143 or an expression vector comprising the nucleic acid molecule of claim 143.
An isolated host cell comprising the nucleic acid molecule of claim 144 or an expression vector comprising the nucleic acid molecule of claim 144.
An isolated host cell comprising the nucleic acid molecule of claim 145 or an expression vector comprising the nucleic acid molecule of claim 145.
A method of preventing and/or treating HIV infection in a patient comprising administering to the patient a therapeutically effective amount of the bivalent, bispecific binding protein of claim 140.
A method of preventing and/or treating HIV infection in a patient comprising administering to the patient a therapeutically effective amount of the bivalent, bispecific binding protein of claim 141.
A method of preventing and/or treating HIV infection in a patient comprising administering to the patient a therapeutically effective amount of the bivalent, bispecific binding protein of claim 142.
Dependencies are inferred from the claim text.